Journal
ANNALS OF ONCOLOGY
Volume 29, Issue -, Pages I38-I46Publisher
OXFORD UNIV PRESS
DOI: 10.1093/annonc/mdx706
Keywords
cfDNA; ctDNA; lung cancer; EGFR; T790M; liquid biopsy
Categories
Funding
- University of Cambridge
- Cancer Research UK [A11906, A20240]
- European Research Council under the European Union [337905]
- Cancer Research UK [20240] Funding Source: researchfish
- European Research Council (ERC) [337905] Funding Source: European Research Council (ERC)
Ask authors/readers for more resources
Molecular profiling has changed the treatment landscape in advanced non-small-cell lung cancer. Accurately identifying the tumours that harbour sensitizing EGFR mutations, the most common targetable molecular alteration, as well as those with acquired resistance mutations (e.g. T790M) on treatment is a high clinical priority. The current clinical gold standard is genotyping of tumour specimens. However, the practical utility of this approach is limited by the lack of available tissue and the potential complications associated with biopsies. With the advent of newer sequencing assays, it has become feasible to assess tumour genomics via a blood sample, termed a 'liquid biopsy'. In this review, we summarize the available techniques for liquid biopsies and their applicability for detecting sensitizing and resistance EGFR mutations and how these results may be used for making treatment decisions.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available